Connect Historical Balance Sheet

CNTB Stock

USD 0.68 0.08 10.53%

Trend analysis of Connect Biopharma Holdings balance sheet accounts such as Total Current Liabilities of 17.9 M, Net Tangible Assets of 2.1 B or Accounts Payable of 8.3 M provides information on Connect Biopharma's total assets, liabilities, and equity, which is the actual value of Connect Biopharma to its prevalent stockholders. By breaking down trends over time using Connect Biopharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Connect Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Connect Biopharma is a good buy for the upcoming year.

Connect Biopharma Inventory

(11.93 Million)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About Connect Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Connect Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Connect Biopharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Connect Biopharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Connect currently owns. An asset can also be divided into two categories, current and non-current.

Connect Biopharma Balance Sheet Chart

At present, Connect Biopharma's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Accounts Payable is expected to grow to about 8.3 M, whereas Other Current Liabilities is forecasted to decline to about 3.3 M.

Other Current Liab Total Current Liabilities Accounts Payable Net Receivables

Total Current Liabilities

Total Current Liabilities is an item on Connect Biopharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Connect Biopharma Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Connect Biopharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Connect Biopharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Connect Biopharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Connect Biopharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	15.9M	24.3M	27.9M	17.9M
Other Current Liabilities	3.5M	3.0M	3.4M	3.3M

Total Current Liabilities Other Current Liab

Connect Biopharma balance sheet Correlations

	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets
Other Current Liab		0.86	0.7	-0.84	0.81	0.16	0.51	0.72	-0.77	-0.7	0.78	-0.65	-0.75	0.64	0.7	0.62	-0.62	0.15	-0.72	-0.65	-0.52	-0.21	-0.81	0.12	-0.75	0.76
Total Current Liabilities	0.86		0.7	-0.86	0.76	-0.23	0.19	0.74	-0.7	-0.48	0.72	-0.61	-0.46	0.58	0.43	0.57	-0.59	-0.1	-0.62	-0.62	-0.45	-0.16	-0.67	-0.08	-0.69	0.4
Net Tangible Assets	0.7	0.7		-0.91	0.34	-0.36	0.26	0.86	-0.69	-0.57	0.97	-0.69	-0.59	0.67	0.69	0.71	-0.7	0.13	-0.78	-0.69	-0.67	0.01	-0.88	0.1	-0.86	0.57
Retained Earnings	-0.84	-0.86	-0.91		-0.54	0.29	-0.15	-0.85	0.87	0.72	-0.95	0.84	0.69	-0.66	-0.54	-0.85	0.84	0.05	0.89	0.84	0.65	0.05	0.92	-0.1	0.94	-0.61
Accounts Payable	0.81	0.76	0.34	-0.54		0.06	0.39	0.31	-0.36	-0.22	0.36	-0.2	-0.28	0.21	0.4	0.22	-0.22	0.29	-0.27	-0.2	-0.17	0.07	-0.35	0.21	-0.29	0.32
Other Assets	0.16	-0.23	-0.36	0.29	0.06		0.63	-0.1	0.01	-0.26	-0.22	0.09	-0.41	0.2	0.32	-0.21	0.21	0.09	0.09	0.1	0.12	-0.59	0.03	-0.12	0.15	0.52
Net Receivables	0.51	0.19	0.26	-0.15	0.39	0.63		0.32	-0.05	-0.18	0.26	0.07	-0.42	0.51	0.87	-0.15	0.15	0.49	-0.04	0.07	-0.09	-0.41	-0.28	-0.06	-0.11	0.63
Other Stockholder Equity	0.72	0.74	0.86	-0.85	0.31	-0.1	0.32		-0.73	-0.65	0.89	-0.72	-0.7	0.93	0.67	0.63	-0.63	-0.28	-0.76	-0.72	-0.79	-0.47	-0.84	-0.36	-0.85	0.66
Total Current Assets	-0.77	-0.7	-0.69	0.87	-0.36	0.01	-0.05	-0.73		0.94	-0.84	0.98	0.86	-0.6	-0.38	-0.95	0.96	0.21	0.97	0.98	0.57	0.21	0.92	-0.13	0.95	-0.73
Common Stock	-0.7	-0.48	-0.57	0.72	-0.22	-0.26	-0.18	-0.65	0.94		-0.75	0.93	0.96	-0.62	-0.45	-0.88	0.88	0.18	0.93	0.93	0.57	0.33	0.89	-0.12	0.88	-0.86
Property Plant Equipment	0.78	0.72	0.97	-0.95	0.36	-0.22	0.26	0.89	-0.84	-0.75		-0.82	-0.76	0.73	0.68	0.82	-0.82	0.03	-0.9	-0.83	-0.73	-0.09	-0.97	0.1	-0.95	0.71
Total Assets	-0.65	-0.61	-0.69	0.84	-0.2	0.09	0.07	-0.72	0.98	0.93	-0.82		0.82	-0.59	-0.3	-0.97	0.98	0.3	0.98	1.0	0.59	0.2	0.9	-0.09	0.95	-0.67
Short Long Term Debt Total	-0.75	-0.46	-0.59	0.69	-0.28	-0.41	-0.42	-0.7	0.86	0.96	-0.76	0.82		-0.72	-0.65	-0.76	0.76	0.06	0.86	0.82	0.61	0.42	0.88	-0.06	0.84	-0.97
Total Stockholder Equity	0.64	0.58	0.67	-0.66	0.21	0.2	0.51	0.93	-0.6	-0.62	0.73	-0.59	-0.72		0.72	0.45	-0.45	-0.32	-0.61	-0.59	-0.69	-0.73	-0.72	-0.53	-0.71	0.73
Property Plant And Equipment Net	0.7	0.43	0.69	-0.54	0.4	0.32	0.87	0.67	-0.38	-0.45	0.68	-0.3	-0.65	0.72		0.25	-0.25	0.42	-0.43	-0.3	-0.46	-0.31	-0.66	0.01	-0.52	0.79
Net Debt	0.62	0.57	0.71	-0.85	0.22	-0.21	-0.15	0.63	-0.95	-0.88	0.82	-0.97	-0.76	0.45	0.25		-1.0	-0.18	-0.98	-0.97	-0.56	0.01	-0.89	0.27	-0.94	0.61
Cash	-0.62	-0.59	-0.7	0.84	-0.22	0.21	0.15	-0.63	0.96	0.88	-0.82	0.98	0.76	-0.45	-0.25	-1.0		0.18	0.97	0.98	0.54	0.0	0.89	-0.26	0.94	-0.59
Non Current Assets Total	0.15	-0.1	0.13	0.05	0.29	0.09	0.49	-0.28	0.21	0.18	0.03	0.3	0.06	-0.32	0.42	-0.18	0.18		0.16	0.3	0.32	0.56	0.0	0.74	0.16	0.11
Non Currrent Assets Other	-0.72	-0.62	-0.78	0.89	-0.27	0.09	-0.04	-0.76	0.97	0.93	-0.9	0.98	0.86	-0.61	-0.43	-0.98	0.97	0.16		0.98	0.65	0.13	0.96	-0.17	0.98	-0.74
Cash And Short Term Investments	-0.65	-0.62	-0.69	0.84	-0.2	0.1	0.07	-0.72	0.98	0.93	-0.83	1.0	0.82	-0.59	-0.3	-0.97	0.98	0.3	0.98		0.59	0.2	0.9	-0.09	0.95	-0.66
Common Stock Shares Outstanding	-0.52	-0.45	-0.67	0.65	-0.17	0.12	-0.09	-0.79	0.57	0.57	-0.73	0.59	0.61	-0.69	-0.46	-0.56	0.54	0.32	0.65	0.59		0.25	0.67	0.25	0.69	-0.57
Short Term Investments	-0.21	-0.16	0.01	0.05	0.07	-0.59	-0.41	-0.47	0.21	0.33	-0.09	0.2	0.42	-0.73	-0.31	0.01	0.0	0.56	0.13	0.2	0.25		0.18	0.8	0.18	-0.43
Non Current Liabilities Total	-0.81	-0.67	-0.88	0.92	-0.35	0.03	-0.28	-0.84	0.92	0.89	-0.97	0.9	0.88	-0.72	-0.66	-0.89	0.89	0.0	0.96	0.9	0.67	0.18		-0.15	0.98	-0.82
Capital Lease Obligations	0.12	-0.08	0.1	-0.1	0.21	-0.12	-0.06	-0.36	-0.13	-0.12	0.1	-0.09	-0.06	-0.53	0.01	0.27	-0.26	0.74	-0.17	-0.09	0.25	0.8	-0.15		-0.07	0.07
Inventory	-0.75	-0.69	-0.86	0.94	-0.29	0.15	-0.11	-0.85	0.95	0.88	-0.95	0.95	0.84	-0.71	-0.52	-0.94	0.94	0.16	0.98	0.95	0.69	0.18	0.98	-0.07		-0.73
Other Current Assets	0.76	0.4	0.57	-0.61	0.32	0.52	0.63	0.66	-0.73	-0.86	0.71	-0.67	-0.97	0.73	0.79	0.61	-0.59	0.11	-0.74	-0.66	-0.57	-0.43	-0.82	0.07	-0.73

Click cells to compare fundamentals

Connect Biopharma Account Relationship Matchups

Connect Biopharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Other Current Liab	1.9M	5.2M	3.5M	3.0M	3.4M	3.3M
Total Current Liabilities	5.8M	18.0M	15.9M	24.3M	27.9M	17.9M
Retained Earnings	(164.1M)	(373.4M)	(463.8M)	(539.3M)	(485.4M)	(509.7M)
Accounts Payable	3.8M	12.7M	11.9M	7.7M	6.9M	8.3M
Net Receivables	265.2K	7.4M	235.9K	51K	58.7K	55.7K
Other Stockholder Equity	7.4M	628.8M	7.2M	628.5M	722.8M	758.9M
Total Current Assets	161.9M	275.4M	158.5M	121.0M	108.9M	203.4M
Common Stock	3.7K	10.4K	9.6K	10K	9K	10.1K
Total Assets	166.2M	291.4M	177.0M	125.9M	113.3M	181.3M
Short Long Term Debt Total	139.9K	124.5K	437.9K	465K	418.5K	327.9K
Total Stockholder Equity	(157.0M)	272.6M	(463.8M)	101.0M	116.2M	122.0M
Property Plant And Equipment Net	2.7M	12.9M	5.5M	4.7M	5.4M	6.4M
Net Debt	(154.6M)	(267.9M)	(79.9M)	(105.5M)	(121.4M)	(127.4M)
Cash	154.7M	268.0M	80.4M	106.0M	95.4M	146.9M
Non Current Assets Total	4.3M	15.9M	18.5M	4.9M	5.7M	5.4M
Non Currrent Assets Other	1.6M	3.0M	34.6K	132K	118.8K	112.9K
Cash And Short Term Investments	156.7M	268.0M	164.6M	118.7M	106.8M	167.6M
Common Stock Shares Outstanding	53.9M	52.3M	55.0M	55.1M	49.6M	43.5M
Short Term Investments	2.0M	677.1	74.7M	12.6M	14.5M	26.4M
Liabilities And Stockholders Equity	166.2M	291.4M	(447.0M)	125.9M	113.3M	81.5M
Non Current Liabilities Total	317.4M	810.7K	911.8K	585K	526.5K	500.2K
Capital Lease Obligations	913K	793K	3.0M	465K	534.8K	508.0K
Inventory	4.9M	(6.7K)	(6.4M)	(14.0M)	(12.6M)	(11.9M)
Other Current Assets	4.9M	7.4M	3.1M	2.3M	2.6M	3.9M
Total Liab	323.2M	18.8M	16.8M	24.8M	22.4M	21.2M
Net Invested Capital	(1.0B)	1.7B	1.1B	101.0M	116.2M	110.4M
Property Plant And Equipment Gross	20.2M	82.2M	51.5M	7.8M	9.0M	8.5M
Accumulated Other Comprehensive Income	(259.4K)	(6.5M)	10.4M	11.9M	13.6M	14.3M
Net Working Capital	1.0B	1.6B	976.1M	96.7M	87.0M	82.7M
Short Term Debt	185.0K	99K	186K	285K	256.5K	186.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Connect Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Connect Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Connect Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Connect Biopharma Holdings Stock:

How To Invest In Connect

Details

Is Connect Stock a good investment?

Details

What is Connect Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.39)

Revenue Per Share

0.438

Return On Assets

(0.12)

Return On Equity

(0.18)

The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Connect Historical Balance Sheet

Connect Biopharma Inventory

(11.93 Million)

About Connect Balance Sheet Analysis

Connect Biopharma Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Connect Biopharma balance sheet Correlations

Connect Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Connect Biopharma balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Assets	+ 0.98	Total Current Assets
Cash And Short Term Investments	+ 0.98	Total Current Assets
Cash	+ 0.98	Total Assets
Non Currrent Assets Other	+ 0.98	Total Assets
Cash And Short Term Investments	+ 0.98	Cash

Cash	- 1.0	Net Debt
Non Currrent Assets Other	- 0.98	Net Debt
Cash And Short Term Investments	- 0.97	Net Debt
Other Current Assets	- 0.97	Short Long Term Debt Total
Net Debt	- 0.97	Total Assets
Non Current Liabilities Total	- 0.97	Property Plant Equipment